Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $15.19.

A number of brokerages have weighed in on VOR. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Monday, August 14th. Stifel Nicolaus decreased their price objective on shares of Vor Biopharma from $16.00 to $15.00 in a research report on Friday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Friday, August 11th. Finally, Wedbush decreased their price objective on shares of Vor Biopharma from $18.00 to $11.00 and set an “outperform” rating for the company in a research report on Friday, August 11th.

Vor Biopharma Stock Performance

NYSE:VOR opened at $2.67 on Tuesday. Vor Biopharma has a one year low of $2.47 and a one year high of $7.57. The firm has a market cap of $180.33 million, a price-to-earnings ratio of -1.31 and a beta of -0.81. The firm’s fifty day moving average is $2.91 and its two-hundred day moving average is $4.21.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). As a group, equities research analysts predict that Vor Biopharma will post -1.82 earnings per share for the current fiscal year.

Institutional Trading of Vor Biopharma

Several hedge funds have recently made changes to their positions in VOR. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 104.6% during the 4th quarter. RA Capital Management L.P. now owns 22,748,880 shares of the company’s stock worth $151,280,000 after purchasing an additional 11,627,907 shares during the period. Artal Group S.A. boosted its position in shares of Vor Biopharma by 422.8% during the 4th quarter. Artal Group S.A. now owns 2,875,581 shares of the company’s stock worth $19,123,000 after purchasing an additional 2,325,581 shares during the period. Laurion Capital Management LP boosted its position in shares of Vor Biopharma by 271.3% during the 4th quarter. Laurion Capital Management LP now owns 3,182,889 shares of the company’s stock worth $21,166,000 after purchasing an additional 2,325,581 shares during the period. BlackRock Inc. boosted its position in shares of Vor Biopharma by 362.9% during the 2nd quarter. BlackRock Inc. now owns 2,164,732 shares of the company’s stock worth $6,689,000 after purchasing an additional 1,697,134 shares during the period. Finally, State Street Corp boosted its position in shares of Vor Biopharma by 1,131.2% during the 2nd quarter. State Street Corp now owns 629,286 shares of the company’s stock worth $1,944,000 after purchasing an additional 578,173 shares during the period. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc, a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.